More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Using risk model-based strategies to determine who should undergo low-dose CT lung cancer screening is more cost effective than current U.S. Preventive Services Task Force guidelines.
TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology.
The data, published in Clinical Imaging, reveal that more than 20% of respondents have witnessed scientific fraud within their department and more than 85% reported the issue of publication bias.
Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures.
